Eli Lilly not doing well in face of patent expirations
The Wall Street Journal notes in an article Eli Lilly Profit Falls 39% on Patent Expirations
The company said that patent expiration of the two treatments caused a 17% decline in volume during the quarter. Cymbalta sales fell 73% to $401.3 million in the quarter, and Evista sales dropped 61% to $108.3 million. Those declines drove a 30% drop in total U.S. revenue to $2.38 billion, the company said.
The company said that patent expiration of the two treatments caused a 17% decline in volume during the quarter. Cymbalta sales fell 73% to $401.3 million in the quarter, and Evista sales dropped 61% to $108.3 million. Those declines drove a 30% drop in total U.S. revenue to $2.38 billion, the company said.
posted by Lawrence B. Ebert at 9:06 AM
0 Comments:
Post a Comment
<< Home